Screening for lipid disorders

被引：13

作者：

Bell, Damon A. ^{[2
,3
]}

Hooper, Amanda J. ^{[2
,4
]}

Bender, Robert ^{[2
]}

Edwards, Glenn ^{[3
]}

van Bockxmeer, Frank M. ^{[4
]}

Watts, Gerald F. ^{[2
,5
]}

Burnett, John R. ^{[1
,2
,4
]}

机构：

[1] Royal Perth Hosp, Dept Core Clin Pathol & Biochem, PathW Lab Med WA, Perth, WA 6847, Australia

[2] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia

[3] St John God Pathol, Dept Clin Biochem, Osborne Pk, WA, Australia

[4] Univ Western Australia, Sch Pathol & Lab Med, Perth, WA 6009, Australia

[5] Royal Perth Hosp, Lipid Disorders Clin, Dept Internal Med, Perth, WA, Australia

来源：

PATHOLOGY | 2012年 / 44卷 / 02期

关键词：

Absolute cardiovascular risk apoB; cardiovascular disease; coronary heart disease; dyslipidaemia; HDL-cholesterol; LDL-cholesterol; triglyceride; DENSITY-LIPOPROTEIN CHOLESTEROL; CORONARY-HEART-DISEASE; APOLIPOPROTEIN-A-I; CARDIOVASCULAR HEALTH; MYOCARDIAL-INFARCTION; CARDIOMETABOLIC RISK; EDUCATION-PROGRAM; MANAGEMENT; CHILDREN; PREVENTION;

D O I：

10.1097/PAT.0b013e32834f90fe

中图分类号：

R36 [病理学];

学科分类号：

100103 [病原生物学];

摘要：

Lipid disorders, also known as dyslipidaemias, are abnormalities of lipoprotein metabolism and include elevations of total cholesterol, low density lipoprotein (LDL) cholesterol, and triglyceride, and reductions in high density lipoprotein (HDL) cholesterol, and can be acquired or familial in nature. Dyslipidaemia is a major risk factor for coronary heart disease and cardiovascular disease (CVD), which is the leading cause of morbidity and mortality in Australia. Dyslipidaemia is defined by laboratory testing and using statistically determined criteria. Although the benefits of detecting and treating dyslipidaemia in patients with known CVD is clear, controversy remains regarding screening asymptomatic individuals who are not known to be at increased cardiovascular risk. This review examines the role of screening in the detection and treatment of individuals with lipid disorders.

引用

页码：115 / 121

页数：7

共 58 条

[1]

[Anonymous], 1992, Pediatrics, V89, P525

[2]

[Anonymous], GUID ASS ABS CARD DI

[3]

[Anonymous], 2001, The Medical Journal of Australia, V175, ps57

[4]

[Anonymous], SCREEN LIP DIS AD US

[5]

[Anonymous], 2008, CLIN GUIDELINES EVID

[6]

Australian Institute of Health and Welfare, 2011, CARD DIS SER

[7]

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials [J].

Baigent, C. ;

Blackwell, L. ;

Emberson, J. ;

Holland, L. E. ;

Reith, C. ;

Bhala, N. ;

Peto, R. ;

Barnes, E. H. ;

Keech, A. ;

Simes, J. ;

Collins, R. .

LANCET, 2010, 376 (9753) :1670-1681

[8]

Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients -: The PRIMO study [J].

Bruckert, E ;

Hayem, G ;

Dejager, S ;

Yau, C ;

Bégaud, B .

CARDIOVASCULAR DRUGS AND THERAPY, 2005, 19 (06) :403-414

[9]

Lipoprotein management in patients with cardiometabolic risk - Consensus conference report from the American diabetes association and the American college of cardiology foundation [J].

Brunzell, John D. ;

Davidson, Michael ;

Furberg, Curt D. ;

Goldberg, Ronald B. ;

Howard, Barbara V. ;

Stein, James H. ;

Witztum, Joseph L. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (15) :1512-1524

[10]

Lipoprotein management in patients with cardiometabolic risk [J].